← Back
Data updated: Mar 10, 2026
HETERO LABS LTD V
CardiovascularInfectious DiseaseNeurology
HETERO LABS LTD V is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include MOXIFLOXACIN HYDROCHLORIDE.
2012
Since
72
Drugs
-
Trials
771
Approved (2yr)
Key Drugs
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
amlodipine besylate
AT1 receptor 3 indications · 2016
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide
AT1 receptor 1 indications · 2016
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID
citric acid
· 2022
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
efavirenz
· 2018
Recent Activity
FINGOLIMOD HYDROCHLORIDE 2026-02-24
Labeling
MYCOPHENOLATE MOFETIL 2026-02-23
Labeling
FINGOLIMOD HYDROCHLORIDE 2026-02-18
Labeling
FINGOLIMOD HYDROCHLORIDE 2026-02-18
Labeling
ARIPIPRAZOLE 2026-02-18
COLCHICINE 2026-02-17
COLCHICINE 2026-02-13
LENALIDOMIDE 2026-02-02
VALACYCLOVIR HYDROCHLORIDE 2026-01-30
Labeling
LACOSAMIDE 2026-01-29
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 40%
8 drugs
Infectious Disease 20%
4 drugs
Neurology 15%
3 drugs
Oncology 15%
3 drugs
Immunology 10%
2 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology
AbbVie big-pharma
Immunology, Oncology, Neurology, Infectious Disease
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular
GSK big-pharma
Infectious Disease, Oncology, Immunology, Neurology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Infectious Disease, Neurology
Active (41)
AVANAFIL ELTROMBOPAG OLAMINE NILOTINIB HYDROCHLORIDE SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID ESLICARBAZEPINE ACETATE LENALIDOMIDE TOLVAPTAN FINGOLIMOD HYDROCHLORIDE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE TERIFLUNOMIDE SILODOSIN PITAVASTATIN CALCIUM OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE OLMESARTAN MEDOXOMIL COLCHICINE OSELTAMIVIR PHOSPHATE ROSUVASTATIN CALCIUM TETRABENAZINE ARIPIPRAZOLE ERLOTINIB HYDROCHLORIDE MOXIFLOXACIN HYDROCHLORIDE TELMISARTAN SIROLIMUS CAPECITABINE LINEZOLID IRBESARTAN ATORVASTATIN CALCIUM LAMIVUDINE ESZOPICLONE ATOMOXETINE HYDROCHLORIDE VORICONAZOLE TEMOZOLOMIDE FAMCICLOVIR PANTOPRAZOLE SODIUM VALACYCLOVIR HYDROCHLORIDE FEXOFENADINE HYDROCHLORIDE ALLERGY CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY LORATADINE ACYCLOVIR NAPROXEN SODIUM
Discontinued (25)
MYCOPHENOLATE MOFETIL LACOSAMIDE LOSARTAN POTASSIUM QUETIAPINE FUMARATE ERTUGLIFLOZIN ALLOPURINOL MONTELUKAST SODIUM FESOTERODINE FUMARATE CLOPIDOGREL BISULFATE MEMANTINE HYDROCHLORIDE TOLTERODINE TARTRATE PIRFENIDONE OSPEMIFENE CINACALCET HYDROCHLORIDE VALSARTAN AMLODIPINE AND OLMESARTAN MEDOXOMIL IMATINIB MESYLATE VALGANCICLOVIR HYDROCHLORIDE ABACAVIR SULFATE AND LAMIVUDINE DONEPEZIL HYDROCHLORIDE BREXPIPRAZOLE ENTECAVIR LEVOFLOXACIN LAMIVUDINE AND ZIDOVUDINE LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
Company Info
- First Approval
- 2012-09-27
- Latest
- 2025-12-29
- Applications
- 81